Follow
Annalisa Mondi
Annalisa Mondi
National Institute of Infectious Diseases L.Spallanzani IRCCS, Rome
Verified email at inmi.it
Title
Cited by
Cited by
Year
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding
D Lapa, F Carletti, V Mazzotta, G Matusali, C Pinnetti, S Meschi, ...
The Lancet Infectious Diseases 22 (9), 1267-1269, 2022
2152022
National institute for the infectious diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management
E Nicastri, N Petrosillo, TA Bartoli, L Lepore, A Mondi, F Palmieri, ...
Infectious disease reports 12 (1), 8543, 2020
1592020
D‟ Offizi G, Marchioni L, Murachelli S, Ippolito G, Antinori A
E Nicastri, N Petrosillo, T Ascoli Bartoli, L Lepore, A Mondi, F Palmieri
National Institute for the Infectious Diseases “L. Spallanzani” IRCCS …, 2020
1532020
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study
MCF Prosperi, M Fabbiani, I Fanti, M Zaccarelli, M Colafigli, A Mondi, ...
BMC infectious diseases 12, 1-11, 2012
1182012
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected …
S Di Giambenedetto, M Fabbiani, E Quiros Roldan, A Latini, G D’Ettorre, ...
Journal of Antimicrobial Chemotherapy 72 (4), 1163-1171, 2017
1032017
Increase in tuberculosis diagnostic delay during first wave of the COVID-19 pandemic: data from an Italian infectious disease referral hospital
F Di Gennaro, G Gualano, L Timelli, P Vittozzi, V Di Bari, R Libertone, ...
Antibiotics 10 (3), 272, 2021
942021
Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people living with human …
A Antinori, S Cicalini, S Meschi, V Bordoni, P Lorenzini, A Vergori, ...
Clinical Infectious Diseases 75 (1), e552-e563, 2022
872022
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons
M Rotger, TR Glass, T Junier, J Lundgren, JD Neaton, ES Poloni, ...
Clinical infectious diseases 57 (1), 112-121, 2013
872013
Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study
C Agrati, A Cossarizza, V Mazzotta, G Grassi, R Casetti, S De Biasi, ...
The Lancet Infectious Diseases 23 (3), 320-330, 2023
842023
Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
A Mondi, A Cozzi‐Lepri, A Tavelli, S Rusconi, F Vichi, ...
African Journal of Reproduction and Gynaecological Endoscopy 22 (1), 2019
692019
Safety and feasibility of treatment simplification to atazanavir/ritonavir+ lamivudine in HIV-infected patients on stable treatment with two nucleos (t) ide reverse …
S Di Giambenedetto, M Fabbiani, M Colafigli, N Ciccarelli, S Farina, ...
Journal of Antimicrobial Chemotherapy 68 (6), 1364-1372, 2013
632013
COVID‐19 in people living with HIV: clinical implications of dynamics of the immune response to SARS‐CoV‐2
A Mondi, E Cimini, F Colavita, S Cicalini, C Pinnetti, G Matusali, R Casetti, ...
Journal of medical virology 93 (3), 1796-1804, 2021
622021
Efficacy and safety of treatment simplification to atazanavir/ritonavir+ lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot …
A Mondi, M Fabbiani, N Ciccarelli, M Colafigli, A D'Avino, A Borghetti, ...
Journal of Antimicrobial Chemotherapy 70 (6), 1843-1849, 2015
532015
Ocular involvement in monkeypox: description of an unusual presentation during the current outbreak
V Mazzotta, A Mondi, F Carletti, F Baldini, R Santoro, S Meschi, ...
The Journal of Infection 85 (5), 573, 2022
432022
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility
M Fabbiani, P Grima, B Milanini, A Mondi, E Baldonero, N Ciccarelli, ...
Antiviral therapy 20 (4), 441-447, 2015
432015
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a …
M Fabbiani, A Mondi, M Colafigli, G D’Ettorre, F Paoletti, A D’Avino, ...
Scandinavian journal of infectious diseases 46 (1), 34-45, 2014
412014
Neuropsychological screening tools in Italian HIV+ patients: A comparison of Montreal cognitive assessment (MoCA) and mini mental state examination (MMSE)
B Milanini, N Ciccarelli, M Fabbiani, E Baldonero, S Limiti, R Gagliardini, ...
The Clinical Neuropsychologist 30 (sup1), 1457-1468, 2016
292016
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy
A Borghetti, G Baldin, A Ciccullo, R Gagliardini, A D'Avino, A Mondi, ...
Journal of Antimicrobial Chemotherapy 71 (8), 2359-2361, 2016
272016
Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital
A Mondi, P Lorenzini, C Castilletti, R Gagliardini, E Lalle, A Corpolongo, ...
International Journal of Infectious Diseases 105, 532-539, 2021
252021
Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital
A Mondi, R Gagliardini, V Mazzotta, S Vita, F Carletti, C Pinnetti, ...
The Journal of Infection 86 (1), 66, 2023
232023
The system can't perform the operation now. Try again later.
Articles 1–20